Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

CI

Cigna (CI) Stock Surges – What's Behind the Rally?

This afternoon we watched Cigna rise 2.9% to a price of $263.71 per share. The Large-Cap Medical Specialities company is now trading -20.8% below its average target price of $332.96. Analysts have set target prices ranging from $270.0 to $378.0 per share for Cigna, and have given the stock an average rating of buy.

Cigna's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 1.9%. The stock's short ratio is 2.63. The company's insiders own 1.59% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Another number to watch is the company's rate of institutional share ownership, which now stands at 89.8%. In conclusion, we believe there is positive market sentiment regarding Cigna.

Institutions Invested in Cigna

Date Reported Holder Percentage Shares Value
2025-06-30 Vanguard Group Inc 10% 25,726,681 $6,784,511,585
2025-06-30 Blackrock Inc. 8% 22,326,264 $5,887,770,628
2025-06-30 State Street Corporation 5% 12,260,613 $3,233,307,512
2025-06-30 FMR, LLC 4% 11,165,790 $2,944,586,268
2025-09-30 Massachusetts Financial Services Co. 4% 10,901,749 $2,874,954,697
2025-06-30 Price (T.Rowe) Associates Inc 4% 10,293,832 $2,714,637,868
2025-06-30 Dodge & Cox Inc 3% 8,950,610 $2,360,410,083
2025-06-30 Sanders Capital, LLC 3% 7,793,018 $2,055,135,713
2025-06-30 JPMORGAN CHASE & CO 2% 6,462,953 $1,704,377,626
2025-06-30 Geode Capital Management, LLC 2% 5,963,102 $1,572,559,422
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS